Seeking Alpha

MacsJV

 
View as an RSS Feed
View MacsJV's Comments BY TICKER:
Latest  |  Highest rated
  • Analyst Interview: Cynapsus Therapeutics Still A Top Pick [View article]
    Hi Jason,
    If the CTH-104 data shoes the 25mg dose slightly exceeds the MTC for a brief time period, but still demonstrates no dose limiting adverse events.... we still have a winner here right?
    Apr 23, 2014. 11:04 AM | Likes Like |Link to Comment
  • Marketing Strategy Could Distinguish Neptune With Industry-Leading Status [View article]
    Nice article, Very thorough research. Another consideration for investing is the potential Acasti brings to the table with Capre. Neptune has 50% ownership in the company and if data is as good as the open labeled study analysts believe Capre could be a billion dollar product. Low risk huge reward with NEPT.
    Mar 20, 2014. 04:51 AM | 1 Like Like |Link to Comment
  • Venaxis: Buy On The Rumor, Sell On The News... Buy On The Sell-Off? [View article]
    Very nice article Dan. Impressive amount of research on this one!
    Feb 7, 2014. 01:27 AM | 2 Likes Like |Link to Comment
  • Biota Pharmaceuticals Inc. And Venaxis Inc.: 2 Upcoming Biopharmaceuticals Catalysts That Could Generate Big Gains [View article]
    Here is the response from my friend in the ER. "Diagnosing appendicitis with ultrasound is challenging in children for a variety of reasons. Lack of operator skill, obesity, anatomic variants are just a few reasons why CT scans are still standard practice. Fact- ER malpractice is rampant and you won't find a hospital in the US that accepts ultrasound as a definitive diagnosis, positive or negative for appendicitis. Hope this helps"
    I am confident that those of us who are long in APPY will see huge gains by March. Of course everyone is entitled to their opinion but at least have the courtesy to get your facts straight before posting. Robert commenting that the "APPY1 test is worthless" belongs on the Yahoo message boards. All due respect show some class and bring some worthy to this discussion or take the time to astound us with a short article.
    Feb 7, 2014. 01:11 AM | 5 Likes Like |Link to Comment
  • Biota Pharmaceuticals Inc. And Venaxis Inc.: 2 Upcoming Biopharmaceuticals Catalysts That Could Generate Big Gains [View article]
    APPY1 test in Europe alone justifies this ridiculous market cap. The futility analysis is a clear indicator results in March will be positive. My friend is an ER Dr. in Georgia and I asked his opinion prior to buying the stock. He told me CT scans are currently the only accurate tool for diagnosis in children. His hospital has a 2 page form highlighting the proven dangers of CT scans in children and parents are required to sign before the scan is performed. Currently about only 50% sign and this poses a major challenge for physicians. He believes that the test would become the standard of care for diagnosing children.
    Feb 5, 2014. 04:54 PM | 5 Likes Like |Link to Comment
  • GlassesOff Chairman Responds: Providing Clarity For Those Who Just Don't See It [View article]
    Shai,
    I have several friends interested in the app however, they have android phones. Can you comment specifically on when the app will be available for android?
    Also, JNapadano mentioned in his article that your company has hired an advertising firm to do a large scale promotion. Can you give us a specific date when the campaign will start?
    Finally, I have 2 friends who have been using the product since the apple launch. One is already glasses free and says it has literally changed his life. The other person has seen dramatic improvements and is close to tossing her reading glasses in the trash. In my opinion anyone critical of this app doesn't wear reading glasses.
    Jan 15, 2014. 09:30 PM | Likes Like |Link to Comment
  • La Jolla Pharmaceutical - Can This Micro-Cap Company Make It In The Big Leagues? [View article]
    Phenomenal article! I think investors need to remember that nothing has changed in terms of value here. The company is still undervalued despite the R/S and I believe patient investors will make profit as we move toward April!
    Jan 14, 2014. 12:01 PM | Likes Like |Link to Comment
  • AcelRx: Huge Potential With Limited Risk [View article]
    This stock has consistently trended lower after positive news. I have been adding shares and will continue to add if the price drops further. Bottom line- the stock will run into the pdufa date next summer. In the meantime, we may get some spikes with ARX-04,Ex-US partnership, or best case scenario a buyout. This is my largest holding and I will likely sell the majority of my shares prior to pdufa announcement in the $13-14 range. If I'm wrong and it only hits $12 I'll settle for a 70% gain.
    Dec 9, 2013. 08:34 PM | 3 Likes Like |Link to Comment
  • AcelRx: Huge Potential With Limited Risk [View article]
    Figaro,
    it is "breakthrough pain"
    ARX-02 is a therapy for breakthrough pain(BTP).
    The sentence is 100% accurate..
    Nov 28, 2013. 10:07 PM | 6 Likes Like |Link to Comment
  • AcelRx: Huge Potential With Limited Risk [View article]
    Not sure I follow you..I only link to one SA article by Scott Matusow and only to mention his analysis on management.
    Nov 27, 2013. 09:19 PM | 1 Like Like |Link to Comment
  • AcelRx: Huge Potential With Limited Risk [View article]
    Daniel, the data is from the U.S.Department of Health and Human Services. Its a meta-analysis of randomized trials. Not sure why the link is missing...I will submit a request to have it added. Thanks for the heads up
    Nov 27, 2013. 07:54 PM | 4 Likes Like |Link to Comment
  • Little-Known Cynapsus Underway To Solve Crucial Problem For Parkinson's Sufferers [View article]
    poor choice of words "crushed"..... low volume, a few nervous investors selling...I think anyone who's aware of this company is already invested and holding for positive results. Also, confirmed that Nathan Cali-Noble Financial still rates the stock a buy with a 12mo PT of 1.75. He updated his coverage on 11/18/13. For anyone who hasn't read the report, its quite detailed but well worth a look. I read it again and remain confident that we have something special here! http://bit.ly/1bDiVTP
    GL
    Nov 20, 2013. 01:07 PM | 2 Likes Like |Link to Comment
  • Little-Known Cynapsus Underway To Solve Crucial Problem For Parkinson's Sufferers [View article]
    Take it with a grain of salt, but Cynapsus put out a paid press release today discussing the potential breakthrough therapy they are developing. Logic tells me that if they were sitting on negative data they wouldn't bother with a paid press release. IMO whether they have the data or not they know its good and the press release is simply a tool to gain some exposure prior to the announcement. Then again the stock got crushed today so who knows...... http://prn.to/1h1L3HG
    Nov 19, 2013. 10:03 PM | 1 Like Like |Link to Comment
  • 2 Bold Speculative Plays In Biotech With Major Upside [View article]
    Brett,
    What is the next catalys for MSTX?
    Nov 14, 2013. 10:21 PM | Likes Like |Link to Comment
  • Salix Pharmaceuticals - Fresh Highs On The Santaurus Deal [View article]
    Great article! What do you anticipate SLXP will have in outstanding shares after the deal is inked? And do you anticipate any near term offering/ dilution in the near term for SLXP. THANKS
    Nov 11, 2013. 05:07 PM | Likes Like |Link to Comment
COMMENTS STATS
28 Comments
47 Likes